NasdaqCM - Delayed Quote USD

Liminatus Pharma, Inc. (LIMNW)

0.0400 0.0000 (0.00%)

As of October 28 at 4:00:00 PM EDT. Market Open.

Chart Range Bar

Loading chart for LIMNW

Previous Close 0.0400
Open 0.0400
Bid 0.3100 x 1000
Ask 0.1706 x 100
Day's Range 0.0400 - 0.0400
52 Week Range 0.0400 - 0.0400
Volume 138
Avg. Volume --
Market Cap (intraday) --
Beta (5Y Monthly) 0.78
PE Ratio (TTM) --
EPS (TTM) --
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

liminatuspharma.com

Full Time Employees

Fiscal Year Ends

Sector

Industry

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-95.65%
Return on Equity (ttm)

--
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-12.52M
Diluted EPS (ttm)

--

Balance Sheet and Cash Flow

Total Cash (mrq)

3.02M
Total Debt/Equity (mrq)

479.85%
Levered Free Cash Flow (ttm)

-10.01M

LIMN

KIDZW

GRMLW

CYCUW

DAICW

U.S. markets close in 4h 40m

Liminatus Pharma, Inc. (LIMNW)

Liminatus Pharma, Inc. Overview

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch